Table 1

Clinicopathological data and results of genotypic studies according to disease stage and outcome at follow up

								Allelic losses
Case1-a	Sex	Age	Macroscopy1-b	Size (cm)	Grade1-c	Stage1-d	p53 IHC1-e	17p	18q	RER phenotype	Follow up (months)	Outcome1-f
ATp 43	M	63	NU	2	M	II	−	Yes	No	No	26	DOD
ATp 53	M	62	NU	2	P	III N	−	No	No	No	64	Alive
ATp 33	F	61	U	1.5	M	II	+	No	No	Yes	126	Alive
ATp 45	F	55	NU	2	W	III	−	Yes	No	No	203	Alive
AT 12	M	37	U	1.5	P	IV N	–^*	Yes	Yes	No	7	DOD
AT 22	M	53	NU	3	M	III N	−E	No	Yes	No	62	Alive
ATp 31	M	50	U	3.5	P	IV N	−	Yes	No	No	12	DOD
ATp 48	M	49	NU	2	W	IV	+	No	No	No	158	Alive
AT 18	M	36	NU	1.5	P	IV	−E	No	No	No	12	DOD
ATp 34	F	63	NU	4	M	III N	+	Yes	Yes	No	51	DOD
AT 25	F	44	U	0.6	P	III N	−E	No	No	Yes	55	Alive
ATp 37	M	46	U	7	P	IV N	+	Yes	Yes	No	26	DOD
ATp 51	F	48	NU	2	M	IV	−	No	No	No	18	DOD
ATp 40	M	60	U	2.5	M	II	+	No	No	No	107	Alive
ATp 49	M	58	U	2	M	IV	+	Yes	No	No	16	DOD
AT 8	M	62	U	2	—	IV N	−^*	Yes	Yes	No	6	DOD
ATp 39	M	61	U	4	M	IV N	−	Yes	Yes	No	12	DOD
ATp 52	M	69	U	1	P	III N	+	Yes	No	No	29	DOD
AT 5	M	57	U	2.5	P	IV N	+E	Yes	No	No	4	DOD
ATp 54	M	47	NU	2.2	P	III N	−	Yes	No	No	22	DOD
AT 14	M	48	U	2	M	III	−E	Yes	Yes	No	22	DOD
ATp 44	M	33	U	2.5	P	III	−	Yes	Yes	No	24	DOD
AT 10	M	66	NU	2	M	II	−^*	Yes	No	No	85	Alive
ATp 57	M	69	U	2.5	M	IV N	+	Yes	Yes	No	19	DOD
AT 23	F	68	U	3	P	IV	−E	No	No	Yes	55	Alive
ATp 38	M	64	U	4.5	M	IV	+	No	No	No	114	Alive
ATp 36	M	61	NU	2	P	II	+	No	No	No	184	Alive
AT 24	M	35	U	2	P	II	+E	Yes	No	No	31	DOD
AT 2	M	59	NU	1.5	P	II	−E	Yes	Yes	No	20	DOD
AT 3	M	73	U	2	M	III N	+E	Yes	Yes	No	24	DOD
AT 4	M	66	U	1.5	P	IV	−E	No	No	No	6	DOD
ATp 6	M	68	U	2.5	M	IV	+	Yes	No	No	16	DOD
ATp 59	M	47	NU	2	P	IV N	+	Yes	No	No	15	DOD
AT 16	M	49	U	1	P	IV N	−E	No	No	No	106	Alive
ATp 56	M	60	NU	1	P	IV N	+	No	Yes	No	21	DOD
ATp 50	M	72	NU	2	—	IV	−	No	No	No	116	Alive
ATp 29	M	59	NU	1.8	P	IV N	+	Yes	Yes	No	16	DOD
AT 15	M	44	U	1.8	P	III N	−E	Yes	No	No	21	DOD
ATp 35	F	65	NU	4	—	IV	−	No	No	Yes	130	Alive
ATp 13	F	60	U	2	P	IV N	+	Yes	Yes	No	9	DOD
ATp 46	M	45	NU	2	M	III	+	Yes	No	No	23	DOD
ATp 58	F	65	U	3.2	P	IV N	−	No	No	No	65	Alive
AT 7	F	46	NU	1	P	II	−E	No	No	Yes	119	Alive
ATp 42	F	73	NU	1	M	II	−	No	No	No	48	Alive
AT 26	M	62	NU	1.5	M	III	−E	No	No	Yes	113	Alive
ATp 47	F	61	U	2	M	III	+	No	No	No	74	DOD
AT 17	F	57	NU	5	W	II	+E	No	No	No	78	Alive
ATp 55	M	63	U	2	M	IV N	+	Yes	Yes	No	25	DOD
ATp 30	F	56	NU	1.5	P	II	−	No	No	Yes	63	Alive
AT 1	F	70	U	3.5	M	IV N	+E	Yes	Yes	No	10	DOD
AT 27	M	69	U	3	M	IV	−E	No	Yes	No	17	DOD
ATp 32	M	58	U	2.5	P	IV	+	Yes	Yes	No	7	DOD
AT 28	F	50	U	4	P	III	+E	No	No	Yes	109	Alive

↵1-a AT, ampullary tumour for which frozen tissue was available. ATp, cases with only paraffin embedded tissue.
↵1-b U, ulcerated; NU, non ulcerated.
↵1-c W, well differentiated; M, moderately differentiated; P, poorly differentiated.
↵1-d I, intraductal; II, infiltration of duodenal submucosa; III, involvement of duodenal muscularis propria; IV, infiltration of periduodenal fat and pancreas; N, nodal metastases.
↵1-e IHC, immunohistochemistry. All cancers with available frozen tissue (AT) had been analysed by DNA sequencing forp53 mutations. Of these 21 cancers, all cases with p53 accumulation by IHC (+E) and three immunohistochemical negative cancers (−^*) showed a p53 gene mutation, while no mutation was detected in the 12 remaining IHC negative cases (−E)
↵1-f DOD, died of disease.